Adaptive Biotechnologies Corporation (ADPT)

NASDAQ: ADPT · IEX Real-Time Price · USD
5.07
-0.11 (-2.12%)
At close: Sep 22, 2023, 4:00 PM
5.00
-0.07 (-1.38%)
Pre-market: Sep 25, 2023, 8:55 AM EDT
-2.12%
Market Cap 733.35M
Revenue (ttm) 189.60M
Net Income (ttm) -190.92M
Shares Out 144.64M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,012
Open 5.21
Previous Close 5.18
Day's Range 5.05 - 5.29
52-Week Range 4.95 - 10.79
Beta 1.21
Analysts Hold
Price Target 12.25 (+141.62%)
Earnings Date Nov 2, 2023

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chroni... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2019
Employees 790
Stock Exchange NASDAQ
Ticker Symbol ADPT
Full Company Profile

Financial Performance

In 2022, ADPT's revenue was $185.31 million, an increase of 20.06% compared to the previous year's $154.34 million. Losses were -$200.19 million, -3.42% less than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ADPT stock is "Hold." The 12-month stock price forecast is $12.25, which is an increase of 141.62% from the latest price.

Price Target
$12.25
(141.62% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Adaptive Announces Launch of Epic Integration for clonoSEQ®

The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers The Adaptive-Epic integration will provide clinician...

12 days ago - GlobeNewsWire

Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...

25 days ago - GlobeNewsWire

Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results

SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...

7 weeks ago - GlobeNewsWire

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023

SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...

2 months ago - GlobeNewsWire

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay's Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers

4 months ago - GlobeNewsWire

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

4 months ago - GlobeNewsWire

Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

4 months ago - GlobeNewsWire

Adaptive Biotechnologies Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive's TCR discovery platform The T-Cell Therapy product candidate co...

4 months ago - GlobeNewsWire

Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

5 months ago - GlobeNewsWire

Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference

SEATTLE, April 25, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the geneti...

5 months ago - GlobeNewsWire

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies Collaboration will cover existing and fu...

5 months ago - GlobeNewsWire

Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023

SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the geneti...

6 months ago - GlobeNewsWire

Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference

SEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...

7 months ago - GlobeNewsWire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results

SEATTLE, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...

7 months ago - GlobeNewsWire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023

SEATTLE, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...

8 months ago - GlobeNewsWire

Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...

9 months ago - GlobeNewsWire

Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting

SEATTLE, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...

10 months ago - GlobeNewsWire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of...

10 months ago - GlobeNewsWire

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)

SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...

10 months ago - GlobeNewsWire

Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...

10 months ago - GlobeNewsWire

New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results

SEATTLE and SALT LAKE CITY, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the a...

11 months ago - GlobeNewsWire

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...

11 months ago - GlobeNewsWire

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers

Integration with the most widely used comprehensive electronic health record will expand clinician and patient access to clonoSEQ Integration with the most widely used comprehensive electronic health ...

1 year ago - GlobeNewsWire

Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022

SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into...

1 year ago - GlobeNewsWire

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million

SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system int...

1 year ago - GlobeNewsWire